New drug therapy can significantly improve survival chances for CLL patients
Combined therapy appears to improve adult leukemia suffers' chances of survival
A new drug therapy can greatly improve the prospects of survival for patients with chronic lymphocytic leukaemia (CLL), according to a new study.
The first-of-its-kind drug, GA101, was found to reduce the relative risk of cancer worsening or fatality during a study follow-up by 86 per cent when combined with chlorambucil chemotherapy.
Results of the CLL11 study are set to be presented at the American Society of Clinical Oncology's cancer conference.
A statement from Roche explained that 22 per cent of patients taking GA101 with chlorambucil were disease-free after treatment, in comparison to a lack of remission in patients receiving chemotherapy alone.
In fact, 75.5 per cent of patients administered GA101 alongside chlorambucil responded to treatment, compared to just 30.2 per cent only given chlorambucil.
Professor Chris Fegan, of the Cardiff and Vale University Health Board in the UK, said: "These significant data mark an exciting step forward in the treatment of this disease."
Related News
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.